PAXTRAVA demonstrated consistent and sustained reductions in intraocular pressure (IOP) over six months, with clinically meaningful reductions of 24-30%. How do these efficacy outcomes reshape the current approach to managing open-angle glaucoma or ocular hypertension?

Considering the observed IOP reductions as early as two weeks post-administration, how crucial is the timing of PAXTRAVA intervention in the management of glaucoma?

How does PAXTRAVA compare to traditional treatments such as topical eyedrops or surgical interventions in terms of efficacy and safety profiles?

From your clinical experience, how do you foresee the integration of PAXTRAVA influencing the overall management of glaucoma patients?

With PAXTRAVA demonstrating a generally well-tolerated safety profile, including no impact on corneal health observed, what strategies do you recommend for managing potential adverse events in clinical practice?

The consistent bioresorption of the implant and durable effect seen in the trial suggest the possibility of repeat dosing without implant stacking. How significant is this feature in addressing the chronic nature of glaucoma?

What are the next steps in research for PAXTRAVA, and what potential studies are needed to further elucidate its role in glaucoma therapy, particularly in larger patient populations or different stages of the disease?

Considering the Phase 2 data and safety profile of PAXTRAVA, how do you envision its integration into existing treatment algorithms and its potential to improve patient outcomes in the long term?